iSpecimen Inc.

iSpecimen Inc. is a US-based company specializing in connecting life science researchers with a diverse inventory of human biospecimens, facilitating critical medical research and development. Founded in 2009 and headquartered in Lexington, US, iSpecimen Inc. operates within the biorepository sector, providing access to human biospecimens.

The company was founded by Christopher Ianelli, who has a history of leading ventures in the life sciences field. iSpecimen has engaged in 7 investment rounds, with its most recent funding occurring on November 29, 2021, through a Private Placement, raising USD 21. 00 mn, bringing the total amount raised to USD 21. 00 mn.

iSpecimen's core offerings revolve around their innovative iSpecimen Marketplace®, a platform designed to connect life science researchers with a comprehensive inventory of human biospecimens sourced from healthcare organizations worldwide. The Marketplace enables researchers to efficiently access various types of biospecimens, including diagnostic remnants, banked samples, and prospective collections. This service addresses the critical challenge of specimen scarcity and quality, which often limits research efforts. iSpecimen caters to a diverse clientele, including academic institutions, pharmaceutical companies, and biotechnology firms, facilitating their access to vital biological materials necessary for medical research and development.

The platform serves a global market, with users spanning multiple geographical regions, including North America, Europe, and Asia, thereby expanding its reach and impact within the life sciences community. iSpecimen generated revenue of USD 9,291,115 in the most recent year, 2024. The company reported an EBITDA of USD -12,945,949 for the same year. iSpecimen's revenue primarily arises from transactions facilitated via its Marketplace, where researchers can source human biospecimens for their studies.

Revenue is supported by transactional fees associated with the procurement of specimens, as well as potential subscription-based services for frequent users. The platform's flagship offerings include access to unique matched sample sets, DNA and RNA sequenced cancer tissue, and comprehensive biospecimen inventories, all of which play a significant role in driving the company's financial performance. iSpecimen plans to leverage recent funding to enhance its software capabilities and increase its workforce significantly over the next year. Following a capital raise of USD 21.

00 mn in November 2021, the company is focusing on expanding its iSpecimen Marketplace® by introducing advanced features and functionalities aimed at improving user experience. Moreover, iSpecimen is targeting geographic expansion into new markets, particularly in Europe and Asia, within the next two years. This strategic growth plan aims to meet the increasing demand for high-quality biospecimens in the global life sciences market.